The University of Texas MD Anderson Cancer Center
Houston, TX

Dr. Cassian Yee is the director of Solid Tumor Cell Therapy in the Center for Cancer Immunology Research and a professor in the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center.

Dr. Yee is a pioneer in adoptive cell transfer (ACT) immunotherapy, which involves taking anti-cancer T cells from patients and then enhancing their anti-tumor capabilities before putting them back into patients. In this area, he helped establish standards for the process, demonstrated that these T cells can confer durable anti-tumor memory, and showed how checkpoint immunotherapy can enhance ACT’s effects. In addition to being a member of CRI’s Scientific Advisory Council, Dr. Yee is a leader of the CRI-SU2C Dream Team, serves on the Postdoctoral Fellowship Review Committee, and is a member of CRI’s global clinical investigator network.

Combining CTLA4 blockade with the transfer of well-characterized, robust antitumor T cells represents an encouraging strategy to enhance the activity of the adoptively transferred T cells and induce antitumor responses.
Let's spread the word about Immunotherapy! Click to share this page with your community.
Copy Link